Related Experiment Video
Updated: Sep 11, 2025

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
An easily overlooked cause of pulmonary arterial hypertension-thiamine deficiency
Qianqian Zhao1, Menglin Li2, Lina Chen3
1Department of Nursing, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Abstract:
Thiamine deficiency (TD), also known as vitamin B1 deficiency, is an often overlooked potential cause of pulmonary arterial hypertension (PAH). It may contribute to the pathological process of PAH through the deficiency of related coenzymes, thereby inhibiting the citric acid cycle. TD can manifest in various clinical forms, including dry beriberi and Shoshin beriberi, the latter characterized by high-output heart failure and lactic acidosis, which can lead to fatal outcomes if not promptly treated. This article reviews the physiological functions of thiamine, the pathophysiological mechanisms of TD, and its relationship with PAH. It explores the hemodynamic changes and diagnostic challenges of Shoshin beriberi and highlights the potential value of thiamine supplementation therapy. Although large-scale randomized controlled trials are currently lacking, minor studies and case reports suggest that thiamine supplementation may benefit PAH patients. Future high-quality research is needed to clarify the role of thiamine in the treatment of PAH.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Pulmonary Embolism I: Introduction
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Peripheral Artery Disease I: Introduction

